Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:TEVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTEVATeva Pharmaceutical Industries$34.04-0.4%$31.83$14.99▼$37.35$39.28B0.867.65 million shs2.71 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTEVATeva Pharmaceutical Industries-0.50%-0.73%+9.00%-0.60%+105.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTEVATeva Pharmaceutical Industries$34.04-0.4%$31.83$14.99▼$37.35$39.28B0.867.65 million shs2.71 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTEVATeva Pharmaceutical Industries-0.50%-0.73%+9.00%-0.60%+105.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTEVATeva Pharmaceutical Industries 2.80Moderate Buy$41.7822.75% UpsideCurrent Analyst Ratings BreakdownLatest TEVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026TEVATeva Pharmaceutical Industries BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $40.004/30/2026TEVATeva Pharmaceutical Industries JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $40.004/30/2026TEVATeva Pharmaceutical Industries UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $42.004/30/2026TEVATeva Pharmaceutical Industries Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$41.00 ➝ $42.004/30/2026TEVATeva Pharmaceutical Industries Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $45.004/20/2026TEVATeva Pharmaceutical Industries Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026TEVATeva Pharmaceutical Industries Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $42.003/4/2026TEVATeva Pharmaceutical Industries Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.00 ➝ $41.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTEVATeva Pharmaceutical Industries$17.35B2.26$3.72 per share9.16$7.16 per share4.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTEVATeva Pharmaceutical Industries$1.41B$1.3325.5911.203.309.01%43.53%8.19%7/29/2026 (Estimated)Latest TEVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2026Q1 2026TEVATeva Pharmaceutical Industries$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion3/31/2026Q1 2026TEVATeva Pharmaceutical IndustriesN/A$0.53N/A$0.31N/A$3.98 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthTEVATeva Pharmaceutical Industries$1.012.97%N/A76.02%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTEVATeva Pharmaceutical Industries1.701.010.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTEVATeva Pharmaceutical Industries54.05%Insider OwnershipCompanyInsider OwnershipTEVATeva Pharmaceutical Industries0.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTEVATeva Pharmaceutical Industries33,9501.15 billion1.14 billionOptionableTEVA HeadlinesRecent News About These CompaniesTEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EUMay 22 at 2:56 PM | finance.yahoo.comTEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EUMay 22 at 12:40 PM | zacks.comTeva Pharmaceutical Industries Ltd. $TEVA Stock Position Decreased by Pinnbrook Capital Management LPMay 22 at 6:34 AM | marketbeat.comThe European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in AdultsMay 21 at 5:25 PM | finance.yahoo.comThe European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in AdultsMay 21 at 12:30 PM | globenewswire.comIFP Advisors Inc Acquires 137,580 Shares of Teva Pharmaceutical Industries Ltd. $TEVAMay 21 at 6:08 AM | marketbeat.comTeva TD Findings Highlight Underdiagnosis And Shape Neuroscience Growth StoryMay 20 at 11:21 AM | finance.yahoo.comTeva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $5,457,268.11 in StockMay 20 at 5:35 AM | insidertrades.comTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Gabelli Funds LLCMay 20 at 3:36 AM | marketbeat.comTeva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?May 19, 2026 | finance.yahoo.comVistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerMay 19, 2026 | finance.yahoo.comTeva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?May 19, 2026 | zacks.comEliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) StockMay 19, 2026 | americanbankingnews.comTeva Pharmaceutical Industries Ltd: Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite ...May 18, 2026 | finanznachrichten.deTeva Pharmaceutical Industries Ltd: Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | finanznachrichten.deTeva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread ImpactMay 18, 2026 | finance.yahoo.comFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | finance.yahoo.comFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | financialpost.comFFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | globenewswire.comTeva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread ImpactMay 18, 2026 | globenewswire.comTeva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx DealMay 16, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTEVA Company DescriptionsTeva Pharmaceutical Industries NYSE:TEVA$34.03 -0.13 (-0.37%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$34.08 +0.05 (+0.15%) As of 05/22/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
